A Role for the Intestinal Microbiota and Virome in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)? by Navaneetharaja, Navena et al.
Journal of
Clinical Medicine
Review
A Role for the Intestinal Microbiota and Virome
in Myalgic Encephalomyelitis/Chronic Fatigue
Syndrome (ME/CFS)?
Navena Navaneetharaja 1,2, Verity Griffiths 2, Tom Wileman 1,2 and Simon R. Carding 1,2,*
1 The Gut Health and Food Safety Research Programme, The Institute of Food Research,
University of·East Anglia, Norwich NR4 7UA, UK; navena.navaneetharaja@ifr.ac.uk (N.N.);
t.wileman@uea.ac.uk (T.W.)
2 Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK; v.griffiths@uea.ac.uk
* Correspondence: simon.carding@IFR.ac.uk; Tel.: +44-1603-251-410
Academic Editor: Luis Vitetta
Received: 18 April 2016; Accepted: 31 May 2016; Published: 6 June 2016
Abstract: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a heterogeneous
disorder of significant societal impact that is proposed to involve both host and environmentally
derived aetiologies that may be autoimmune in nature. Immune-related symptoms of at least
moderate severity persisting for prolonged periods of time are common in ME/CFS patients and
B cell depletion therapy is of significant therapeutic benefit. The origin of these symptoms and
whether it is infectious or inflammatory in nature is not clear, with seeking evidence of acute or
chronic virus infections contributing to the induction of autoimmune processes in ME/CFS being
an area of recent interest. This article provides a comprehensive review of the current evidence
supporting an infectious aetiology for ME/CFS leading us to propose the novel concept that the
intestinal microbiota and in particular members of the virome are a source of the “infectious” trigger
of the disease. Such an approach has the potential to identify disease biomarkers and influence
therapeutics, providing much-needed approaches in preventing and managing a disease desperately
in need of confronting.
Keywords: myalgic encephalomyelitis; chronic fatigue syndrome; intestinal microbiota; dysbiosis;
microbiome; virome
1. Introduction
What Is ME/CFS?
Descriptions of outbreaks of illness resembling those of myalgic encephalomyelitis/chronic
fatigue syndrome (ME/CFS) have been reported for more than two hundred years with the term
benign myalgic encephalomyelitis proposed in the late 1950s as a name for a group of symptoms
including protracted muscle pain with paresis, emotional disturbances and encephalitis [1]. As a result
of an outbreak of illness in Lake Tahoe, USA in the mid-1980s, the name CFS describing the main
symptom of the illness was proposed, with the first case definition for CFS being produced in 1988 [2].
Diagnosis does however remain difficult, relying principally on exclusion, with the current estimate
of 0.1%–0.2% of the population being affected [3] and multiple studies showing that it can take more
than five years for patients to be diagnosed [4]. Affected individuals are predominantly women and
minority groups, of an average age of 33, though the disease has been reported to affect those as young
as 10 and as old as 77 [5–8]. At least one-quarter of patients are house- or bed-bound at some point
in their lives [5,9] with as few as 6% of individuals returning to pre-morbid levels of function [3].
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The societal impact of ME/CFS is therefore considerable with the annual direct and indirect economic
cost estimated to be between $17 and $24 billion [10].
The diagnosis of ME/CFS is commonly based on the Fukuda [11], Oxford [12] and/or the
International Consensus Criteria (ICC) classifications [13], that identify the core symptoms of the
condition as the presence of neuropsychological features such as a distinguishing post-exertional
malaise, sleep disturbance and autonomic symptoms. A key distinction between classifications
is the acknowledgment of persistent fatigue for six months or more, a requirement not made by
the ICC classification. The Fukuda and Oxford classifications are not considered as ME-specific as
the Canadian definition, which identifies symptom clusters of ME with emphasis on neurosensory,
immune, gastrointestinal and genitourinary manifestations of the disease. While such discrepancies
in diagnostic consensus are apparent, there is no doubt that their presence can lead to profound
losses of daily function in a subset of patients. In a report published in 2015 The Institute of Medicine
(The National Academies, Washington, D.C., USA) proposed a new diagnostic algorithm focusing on
its central symptoms, emphasising that studies aimed at assessing the natural history of the disease and
its temporal characteristics are essential for a better understanding of the causes, improved diagnosis
and treatment of ME/CFS [14].
All ME/CFS case definitions include some inflammatory symptoms and signs although their
prevalence and severity ranges widely across different studies that vary in time period, location and
case definition. However, immune-related symptoms of at least moderate severity that persist for
prolonged periods of time (>6 months) are commonly reported in ME/CFS patients [15]. The origin of
these symptoms and whether it is infectious or inflammatory in nature is not clear with several studies
seeking evidence of acute or chronic infections and/or underlying immune impairment in ME/CFS,
which is discussed in more detail below. The recent link between ME/CFS and xenotropic murine
leukemia virus-related virus (XMRV) [16] has largely been disproven and attributed to laboratory
contaminants [17]. This highlights the need for further carefully controlled studies that use sensitive
methodologies to detect infectious agents, that can produce findings which can be independently
replicated in different cohorts of ME/CFS patients [18]. Here, we present a critique of the current
knowledge and understanding of infectious agents in the pathogenesis of ME/CSF, with the aim of
providing focus for further research, exploring the potential impact of the intestinal microbiome and
virome using considered and sensitive study designs.
2. Infections and ME/CFS
Reports dating back more than 60 years describing disease outbreaks in “closed populations”
such as in hospitals and convents producing symptoms consistent with ME/CFS raised the possibility
of an infectious aetiology or, an association of infection with disease onset [1,19,20]. ME/CFS patients
often present with flu like symptoms with an acute onset presentation being more common in these
patients than in those suffering from chronic fatigue only [21]. Population based studies however, have
shown a predominance of a gradual over acute infectious onset to be more consistent with a chronic
infection or reactivation of a latent infection [8]. In view of this and the overlapping symptoms of
ME/CFS with chronic virus infections, it is not surprising that numerous attempts have been made to
identify viruses as a trigger of ME/CFS (Tables 1 and 2).
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Table 1. Summary of studies of EBV infection and ME/CFS.
Study Participants (Diagnostic Criteria) Study Design Analysis Findings Reference
253 infected patients including 68 EBV+
(Fukuda); 16–77 years, 57% male;
ě3/12 SOMA scale for disease severity.
Controls: Self-reported group
Prospective cohort
following EBV infection Serum Abs 28/253 (11%) developed ME/CFS following EBV
Hickie et al.,
2006 [22]
250 primary care patients with an URTI
or glandular fever (Fukuda + Oxford);
16–65 years of age.
Prospective cohort Interview and EBVserum Ab
47% acquired acute CFS after infection cf. to 20%
after URTI (RR 2.3, 95% CI 1.3–4.1).
CFS prevalence at 6 months post glandular fever
was 9%–22% cf. 0%–6% after URTI (RR 2.7–5.1).
White et al.,
1998 [23]
2 cohorts of 63 and 387 patients (Fukuda);
27–63 and 20–78 years of age; 73% and
63% women respectively.
Controls: 61 healthy controls
Comparing patients
vs. controls Serum EBV Ab and Ag
Attenuated T and B cell responses in CFS patients.
EBNA-IgG titers reduced in 10% of CFS patients.
Reduced number EBNA-1- and VCA-antibody
secreting memory B cells in 76% of patients.
EBV-induced secretion of TNFα and IFN-γ was
significantly lower. Lower % EBNA-1-specific
TNF-α/IFN-γ/IL-2+ CD4 and CD8 T-cells.
EBV load in blood immune cells, EBER-DNA >
BZLF-1 RNA in CFS patients suggesting more
frequent latent replication.
Loebel et al.,
2014 [24]
58 (Fukuda + CDC); mean 44 years of
age; 75% female.
Controls: 68 matched controls; average
age 53 years and 73% women
Case control Serum anti-VCA andEA Ab
100% VCA and EA IgM+ when EBV positive.
Diagnostic use in a ME/CFS subset?
Lerner et al.,
2004 [24]
14 (Sharp + Holmes), mean 35 years of
age, 64% women
Cohort of travelers with
CFS symptoms Serum Abs
3/14 EBV IgM+
(11/14 CMV IgM+)
Gascon et al.,
1995 [25]
301 IM patients including 39 CFS patients
(Fukuda); mean 16 years of age;
90% female; baseline characteristics
predicted severity of CFS.
Controls: 50 IM patients fully recovered
by 6 months; age 16 years and
74% female)
Prospective nested
case control
longitudinal study
Self-reporting CFS 39 developed ME/CFS with 50 controls reportingfull recovery.
Jason et al.,
2014 [26]
301 IM patients with 39 CFS patients
(Fukuda); 12–18 years of age; 90% female;
disease defined by length of
time affected.
Cohort study
determining ME/CFS
incidence at 6, 12 and
24 mouths
Self-reporting ME/CFS
13% at 6 mouths
7% at 12 mouths
4% at 24 mouths
Katz et al.,
2009 [27]
Ab, antibody; RR, relative risk; CI, confidence interval; IM, infectious mononucleosis; UTRI, upper respiratory tract infection.
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Table 2. Studies of non-EBV virus infections and ME/CFS.
Virus Study Participants (DiagnosticCriteria) Study Design Analysis Findings References
Human Herpes
Virus 6 (HHV-6)
35 ‘adults’ (CDC + Fukuda);
71% female; 27/35 with severe
disease vs. 21 Multiple Sclerosis
patients vs. 25 healthy controls
Case control Serum anti-virus Abs
32/35 (91%) patients HHV-6 gp110a
IgG+ cf. 88% vs. 22/25 controls.
23/35 (65.7%) patients HHV-6 p41/38a
IgG+ cf. 20% vs. 5/25 controls.
Ablashi et al.,
2000 [28]
Parvovirus B19
48 (Fukuda); 37 ˘ 13 years of age;
78% female; severity not assessed
vs. 35 otherwise healthy controls
with mild GI upset; 66% female,
46 ˘ 17 years of age
Case control quantifying
viral loads
PCR detection of virus in
GI-biopsy and blood
38%–40% gastric and duodenum
biopsies B19+ cf. 14% controls (OR 3.93,
p = 0.008). No virus detectable in
the blood.
Fremont et al.,
2009 [29]
Enterovirus
48 (Oxford); 35.3–37.5 mean age,
54% male, severity not assessed vs.
29 controls with ‘normal muscle’
Case control detecting
virus RNA
RT-PCR detection in
muscle biopsies
20.8% of biopsies virus RNA+ cf. none
detected in controls.
9/10 enterovirus RNA+ patients had
abnormal lactate response to exercise.
Lane et al.,
2003 [30]
165 (CDC); ages, sex and disease
severity not reported; duration of
illness: 5.0 ˘ 4.5 years vs.
22 healthy controls vs.
12 gastric diseases
Case control study RT-PCR detection viralRNA in GI-biopsy
82% of biopsies VP1+ cf. 20%
of controls.
~33% of patients virus RNA+ over
4 years, 5 with transient growth of
non-cytopathic enteroviruses.
Chia et al.,
2008 [31]
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2.1. Viral Infection
Numerous viruses have been associated with the initiation or perpetuation of ME/CFS, including
Epstein Barr Virus (EBV) [22,23], Ross River virus [22], human herpesvirus-6 (HHV-6) [28], parvovirus
B19 [29,32], hepatitis C virus, human retroviruses and enteroviruses [33]. Amongst these, EBV is most
frequently identified as a possible viral trigger of ME/CFS (Table 1). However, in considering the
difficulties of detecting active, pathological infections and distinguishing an active infection from
reactivation of a latent infection, the vast majority of studies rely on indirect and/or anecdotal evidence.
In particular, heavy reliance is placed on detecting the presence, or elevated levels, of virus-specific
antibodies in ME/CFS patients’ sera. Whilst high titers of EBV antibodies that includes reactivity to
viral capsid antigen (VCA) have been found in subsets of patients compared to healthy individuals who
were previously infected with EBV [24,34], not all studies have replicated these findings [29,35–40].
In addition, the presence of serum antibodies to EBV, HHV-6 and CMV viruses are not specific to
ME/CFS and are associated with other diseases and they can be found in asymptomatic individuals [41].
Also, elevated levels of these antibodies may result from unrelated conditions in subjects with an altered
immune system that leads to virus reactivation. Other approaches that have been used to attempt to
demonstrate causality include the use of animal models in which animals, usually mice, are inoculated
with specific viruses or their products in an attempt to reproduce disease symptoms and through the
use of antiviral medications in patients.
Glaser and colleagues used mice to investigate the contribution of EBV proteins expressed during
viral replication in disease induction [42–44]. Stimulation of the mouse immune system by dUTPase can
induce immune-modulatory effects that resemble the clinical symptoms observed in ME/CFS sufferers
including reduction in body mass and physical activity that correlated with increased production of
inflammatory cytokines (TNFα, IL-1β, IL-6) together with enhanced Natural Killer (NK) cell activity
and IFNγ synthesis. Of note, EBV dUTPase was shown to stimulate production of cytokines by human
PBMCs [45]. Although these studies suggest that viral products, such as non-structural EBV-encoded
protein, can attach to cellular membranes, enter multiple organs and induce immune-modulatory
effects that resemble the clinical symptoms observed in ME/CFS sufferers [46], such findings need to
be corroborated using larger cohorts of patients and appropriate control groups.
The successful use of antiviral medication in ME/CFS patients could provide support for a virus
infection as a trigger for ME/CFS or rather, a perpetuating factor for the disease. Montoya et al.
conducted a double-blind, placebo controlled trial using the anti-viral agent valganciclovir in a total
of 30 patients with elevated IgG antibody titers against either EBV or HHV-6. After 6 months, the
treatment arm showed significant improvement in measurements of fatigue using the fatigue severity
scale, along with significant beneficial changes in monocyte and cytokine levels [47,48]. However, the
small numbers in each treatment arm limit the study findings, which are further exacerbated by
reported high dropout rates by the end of the study. Furthermore, although high IgG titres are
a surrogate marker for intense infection with both EBV and HHV-6, it may also be a sign of an affective
immune system able to produce large amounts of antibody in response to infection.
A prospective study of patients with elevated serum antibody titers to EBV in addition to
CMV or HHV-6 resulted in a 75% response rate to long-term valacyclovir and/or valganciclovir
treatment, reporting significantly increased long-term Energy Index Point Scores, with improvements
in cardiac, immunologic and neurocognitive abnormalities [49]. However, another double blind,
placebo controlled trial of acyclovir in a small number of ME/CFS patients (N = 27) showed no
clinical difference in treated versus placebo controls [50]. An alternate approach is based upon
enhancing antiviral defences in ME/CFS patients in which it is assumed they have an unidentified,
underlying viral infection and using various immune activating agents to boost the immune system
and antiviral responses. A pilot single blind, placebo-controlled study measuring the clinical effect
of the immunostimulatory drug Isoprinosine in sixteen CFS patients, resulted in the improvement of
symptoms in 60% of patients. Patients who reported improved clinical parameters also showed
significantly enhanced NK cell activity which correlated with the duration of therapy and to
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significantly increased numbers of CD4+ T helper cells and IL-12 levels at week 28 [51]. A recent
clinical trial of Rintatolimod, an agonist of Toll-Like Receptor (TLR)-3 which, via recognition of double
stranded RNA elicits production of anti-viral type 1 interferon, showed objective improvements
in exercise tolerance and a reduction in symptoms compared to placebo after 40 weeks, indicating
a microbial role in ME/CFS [52].
Evidence to the contrary that virus infection is an aetiological factor in ME/CFS has come from
the analysis of monozygotic twins discordant for disease in which no differences in the virus profile
and expression was found in healthy versus disease twin pairs [36]. Other studies comparing ME/CFS
patients with healthy control subjects have failed to identify any significant differences in virus
content and/or serum levels of antibodies specific for parvovirus B19 [53], HHV-6A, HHV-6B or
HHV-7 [54–57]. The reasons for these apparent discrepancies are unclear but may be related to the
inherent difficultly of detecting active infections and discriminating it from reactivation of latent
infection, other unrelated conditions and immune alterations. They may also be related to the use of
different disease classifications and patient inclusion/exclusion criteria and stratification and the use of
different analytical methodologies. Many studies that rely on blood samples for detecting evidence of
virus infection may miss enteroviruses, parvovirus, or herpes virus infections that continue to persist
in the gut, brain or heart tissue, respectively.
A role for enteroviruses in ME/CFS has been suspected for many years [30,58,59] with the study of
Chia and colleagues identifying a higher prevalence of enterovirus infection in gastric biopsy samples
of ME/CFS patients with significant gastrointestinal symptoms (82%), compared to control subjects
(20%) [31]. Others however, have found no increased incidence of enterovirus infection in ME/CFS
patients [60] (Table 2).
2.2. Non-Viral Infection
The evidence of a bacterial infection as a trigger of ME/CFS has only been described in case
reports of Q-fever and Chlamydia pneumonia and unlike studies focusing on viral infection, none
have focused on the effect of antibacterial therapy on symptom relief in ME/CFS cohorts [61–63].
The association between ME/CFS and parasitic [64], or fungal [65] aetiologies have also been limited
and inconclusive. Currently, there is insufficient evidence to conclude that ME/CFS is caused by
a bacterial infection or that the disease is sustained by an ongoing infection.
3. Immune Impairment in ME/CFS
Studies of the immune status of ME/CFS patients are aimed at biomarker discovery and
identifying distinguishing features of immune profile or function that can provide insights into
the (immuno)pathogenesis of ME/CFS. The most consistent finding is a reduction in the function of
NK cells that play an important role in immune surveillance and viral immunity [66]. Impaired NK
cell function is a common finding in patients [67–69] although the absolute number of NK cells is not
affected by disease states [39,67–74]. Overall, studies have lacked consistency and reproducibility, with
different studies focusing on different identity markers and different indicators of cytotoxic activity.
The current literature does not therefore convincingly establish a correlation between NK cell function
and disease severity.
The usefulness of low NK cell cytotoxicity as a biomarker for ME/CFS is further questioned by
a the presence of a similar phenomenon and impaired NK cell function in rheumatoid arthritis, cancer
and endometriosis [75–77] as well as in healthy individuals who are older, smoke, psychologically
stressed, physically deconditioned or sleep deprived [78–80]. Evidence of specific changes in NK
function including altered perforin and granzyme concentrations [81] have also been described
although these findings have not been independently verified.
Other indicators of immune alteration in ME/CFS patients come from the comparative analysis
of cytokine levels in the blood or more rarely, other sites such as cerebrospinal fluid. The majority of
studies are limited by examining a select few cytokines in small numbers of patients most of which
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have failed to yield significant findings. Despite this, some studies have reported raised levels of
TNFα in ME/CFS patients [70,82–84] which is of particular interest as it is a mediator of malaise and
a feature of CNS inflammatory disorders [85,86] and via its action on vaso-vagal reflex circuits in the
brainstem can disrupt autonomic control [87]. However, the significance of such changes in TNFα or
any other cytokine in ME/CFS patients is uncertain since they may simply reflect immune activation
and can be altered in various chronic inflammatory disorders and are therefore unlikely to be specific
to ME/CFS. Consistent with this interpretation are the results from a study using monozygotic twins
discordant for ME/CFS that found no evidence of differences in pro-inflammatory cytokine levels
in the affected versus non-affected twin [88]. The use of different sampling methods, diagnostic and
inclusion criteria and sources of patients and control subjects may account for contrasting outcomes
from immune function studies in ME/CFS patients, with some studies lacking suitably matched
controls. Moreover, relatively few studies were longitudinal [68], often relying on a single sample and
time point of analysis unable to account for the natural history of ME/CFS [6].
3.1. Is ME/CFS an Autoimmune Disease?
The positive outcome of clinical trials of Rituximab (trade names Rituxan, MabThera and Zytux),
a chimeric monoclonal antibody that recognises the pan-B cell surface antigen CD20, in Norwegian
cohorts of ME/CFS patients arguably provide the strongest evidence to date of immune alterations
and dysfunction in ME/CFS [89] and that the disease may be autoimmune in nature [90] (see below).
The drug has previously been successfully used in the treatment of rheumatoid arthritis [91]. Rituximab
treated ME/CFS patients reported an overall response rate of 67% compared to 13% in the placebo
arm, with significant reductions in fatigue scores after 8 months. The transient symptom improvement
is consistent with a mode of action of Rituximab in depleting autoantibody-producing B cells and with
an autoimmune-based pathogenesis of ME/CFS. Confirming these findings and positive Rituximab
treatment outcomes in additional larger, multi-centre based trials would make the case for ME/CFS
being an autoimmune disorder more compelling. Other immunophenotyping-based studies of
ME/CFS patients that have described alterations in B cell populations [92,93] and greater numbers of
naïve B cells, provide additional indirect evidence in support of this interpretation [94,95].
Identifying the origin and nature of the autoantigens that drive autoimmune responses are
important in establishing ME/CFS as an autoimmune disorder. Several putative self-reactive
antigens have been identified including serotonin, dopamine and cholinergic neurotransmitters [96,97]
(Table 3). For example, one study has reported that individuals with ME/CFS have increased
5-hydroxytryptamine (HT) autoimmune activity associated with activation of inflammatory pathways
and increased bacterial translocation which has led to analogies with neuroimmune aspects of multiple
sclerosis [98]. How and where in the body autoreactive immune cells are activated is a matter of
conjecture. However, given its continuous exposure to a vast number of microbes, immune cells and
immune processes, we propose the gut as an attractive and important source of autoreactivity with the
potential to cause chronic debilitating disease.
Table 3. Autoantibodies in ME/CFS patients.
Antigen Target of Autoantibodies Reference
Cardiolipin Hokama et al., 2008 [99]Hokama et al., 2009 [100]
Nuclear envelope antigens Konstantinov et al., 1996 [101]
Neuronal cell Buchwald et al., 1991 [102]
68/48 kD protein antibodies Nishikai, M., 2007 [103]
Serotonin, microtubule-associated protein 2 and
muscarinic cholinergic receptor-1 Bassi et al., 2008 [104]
5-HT, gangliosides and phospholipids Klein and Berg, 1995 [105]
Muscarinic cholinergic receptor Tanaka et al., 2003 [97]
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3.2. A Gut Origin for Autoimmunity?
A novel premise involving an autoimmune association in ME/CFS is of a microbial trigger
introduced not by an externally acquired pathogen and infection, but by microbes already residing
within that host (microbiome), the vast majority of which comprise the intestinal microbiota.
Whilst alterations in the composition of the intestinal microbiota (dysbiosis) have been described and
associated with different disease states in both experimental animals and humans, the most compelling
causal evidence of the direct involvement and a requirement for the intestinal microbiota in disease
initiation comes from the use of sterile, germ-free animal (mouse) models of autoimmune disease [106].
In most but not all of the disease models, that includes inflammatory bowel disease, autoimmune
arthritis, Type 1 diabetes and systemic lupus erythematosus, the severity and/or incidence of disease
is reduced or absent under germ-free conditions consistent with the microbiota being a ‘trigger’ for
disease progression. It is important to note however, that the identity of the pathobionts able to
promote disease after colonization (conventionalisation) of the germ-free mice has not been established
for any of these diseases. The absence of a mouse model that faithfully reproduces the hallmark
features of human ME/CFS is a constraint and limiting factor in determining if or how the microbiota
contributes to the pathogenesis of ME/CFS.
How do members of the intestinal microbiota gain exposure to the hosts’ immune system?
Intestinal dysbiosis is thought to promote or be associated with altered permeability of the intestinal
epithelial barrier, termed ‘leaky gut syndrome’. Disruption of epithelial junctional complexes that
normally tightly bind adjoining cells (tight junctions) in the boundary epithelium provides a portal
of entry for the translocation of bacteria or bacterial components into mesenteric lymph nodes or the
systemic circulation [107,108]. This can, if the disruption is extensive and not effectively resealed lead
to local and systemic immune cell activation and resulting production of pro-inflammatory mediators
and cytokines that can further disrupt epithelial tight junction [109]. A pertinent example is the
aetiology of Guillain-Barre syndrome, where Campylobacter jejuni lipopolysaccharide (LPS) that is
structurally similar to host cell gangliosides leads to the production of cross-reactive antibodies that
target and damage host neurones leading to paralysis [110].
The junctional complexes of intestinal epithelial tight junctions also display striking similarities to
endothelial tight junctions in the blood-brain barrier (BBB), as seen in a study involving HIV-1 infected
mice treated with LPS [111]. Systemic administration of LPS was shown to disrupt the integrity of
the BBB, permitting the migration of HIV-1 infected monocytes to enter the brain from the peripheral
circulation. LPS is thought to disrupt the intramembranous junctional complex proteins such as ZO-1
and occludin, compromising the structural integrity of the BBB. Activation of microglia can occur by
LPS via its binding to CD14 and TLR-4, which initiates an inflammatory reaction within the cranial
circumventricular organs [112]. Experimental studies have shown that chronic intestinal inflammation
elicited by bacterial products can result in neurological disease, with bacteria-derived LPS thought
to play a role in the generation of antibodies cross reactive with host lipoproteins and the aetiology
of multiple sclerosis [113]. Of relevance to ME/CFS, one study has reported significantly higher
titres of serum antibodies to LPS in ME/CFS patients with abdominal discomfort than in controls,
concluding that gastrointestinal symptoms were associated with increased bacterial translocation,
which is a potential driver of systemic inflammatory processes [82]. Support for this hypothesis has
been obtained in independent studies reporting a correlation between the translocation of enteric
bacteria with disease activity in subsets of ME/CFS patients [114]. The intestinal microbiota may
therefore serve a role in initiating or perpetuating immune activation, bacterial translocation and
autoimmune processes, which have all been implicated in the pathogenesis of ME/CFS [90].
4. Could the Intestinal Microbiota Play a Role in the Development of ME/CFS?
The co-existence of ME/CFS and gastrointestinal symptoms is well documented [115] with
one study reporting that 92% of ME/CFS patients have co-existent irritable bowel syndrome (IBS) [116]
and with studies of the immunological relationship between the two conditions showing increased
mucosal and systemic levels of pro-inflammatory cytokines IL-6, IL-8, IL-1β and TNFα [117,118].
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Initial analyses of bacterial populations using stool samples from ME/CFS patients found higher
distributions of Escherichia coli as a percentage of total aerobic microbes compared to healthy controls
(92.3% versus 49%), however these findings were reported in a scientific meeting, with unspecified
methodology [119]. D-lactic acid producing Enterococcus and Streptococcus species were also found
to be significantly increased in ME/CFS patients, which was confirmed by culture with NMR-based
metabolic profiles showing that samples from ME/CFS patients were associated with lower levels of
Bifidobacteria [120]. Other studies have extended these observations, showing an association between
increasing Enterococcal counts and the severity of reported neurological and cognitive deficits [121],
with a larger study describing an association between significant reductions in Bifidobacteria, higher
aerobe to anaerobe ratios and more severe gastrointestinal functional deficits [122]. Furthermore, 77% of
CFS patients have been found to have small intestinal bacterial overgrowth [123], which displays some
similar clinical symptoms to ME/CFS [121].
To date, only one study has utilised sensitive next-generation sequencing technology to profile
the microbiota in ME/CFS by comparing Belgian and Norwegian patients to healthy controls [124].
Discriminant function analysis revealed distinct microbiota populations in patients and controls in both
countries based on bacterial genera (p = 0.022), with Norwegian patients displaying highly significant
differences in intestinal microbiota compositions compared to Norwegian controls (p < 0.001), typified
by significant variations in Firmicutes populations, with a 50-fold decrease (p = 0.00001) in the Firmicutes
genera Holdemania and a 20-fold increase (p = 0.003) in Lactonifactor. The geographical differences
in microbiota compositions were attributed to Norwegian patients reporting a longer duration of
illness, suggesting that the intestinal composition is altered in ME/CFS patients. Differences in
experimental protocols and bacterial DNA extraction techniques may explain the contrasting outcomes
of these studies, and emphasizes the need to compare larger cohorts with reliable matched subjects.
Several factors govern why microbiota profiling studies in ME/CFS lack apparent consistency
including, patient related issues such as inconsistent phenotypic classifications, small and often
unpowered sample numbers and technical issues related to differences in the reliability, sensitivity
and coverage of microbial sequence detection provided by different DNA extraction and 16S RNA
amplification protocols, different sequencing platforms and the reliance on single samples and time
points of analysis that can only provide a snapshot of microbiota compositions. Despite demonstrations
of altered diversity and stability of the intestinal microbiota in ME/CFS, it is not yet possible to say that
a specific microbial signature exists in ME/CFS. Care must also be taken in attempting to establish such
a disease microbiota signature in view of the heterogeneity in symptoms and subgroups presented
in ME/CFS.
5. What Next for ME/CFS Microbiome Studies?
Microbiome studies have to date almost exclusively focused on defining changes in intestinal
bacterial population; recently however, the remit has broadened to assess the non-bacterial
microorganisms of the intestine. Of particular interest are the viral components of the microbiota.
Components of the virome, specifically bacteriophages, which make up 90% of the gut virome
composition [125] are primary drivers of bacterial diversity and influence community structure by both
eliminating and introducing traits to their host species via the horizontal transfer of genes [126–128].
So far, the impact of the intestinal virome in healthy and disease states has received very little
attention, but in its unexplored functional role it is possible that the phages in the virome will have
as yet unexplored, explored effects. These can be indirect effects resulting from changes to bacterial
populations, or direct effects following stimulation of the immune system if they cross gut epithelial
barriers and enter the host.
5.1. The Intestinal Virome
The virome has been shown to be more personalized and stable than bacterial intestinal
communities [129], with the profiling of viral communities in female monozygotic twins and their
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mothers finding limited intra-personal variation compared to high inter-personal viral variation [130].
This variability has been attributed to both the presence of individual intestinal bacteria and the rapidly
evolving nature of viral populations. The longitudinal sampling of a healthy male over a period of
2.5 years revealed that 80% of viral contigs, which are contiguous reads of sequenced DNA, persisted
over that period. Variations over time were attributed to diversity-generating retroelements, a family
of genetic elements that serve to diversify DNA sequences and CRISPR arrays, short segments of
prokaryotic DNA within bacterial and archaeal genomes that can establish if a microbial population
has been previously infected by phage [130].
Virome sequencing has lagged behind bacterial microbiome studies; principally as a result of
technical limitations [131]. Recent viral metagenomic studies have displayed limited capacities to
assign viral sequences to taxa, with current databases lacking appropriate depth to identify viruses,
let alone link specific bacteriophages to individual bacteria or disease states. Shotgun metagenomics
is a high throughput technique that allows direct analysis of random pieces of DNA sequences from
the genomes of whole samples and initial reads have been used to assemble complete genomes of
phages and viruses that infect humans [132,133]. However, metagenomic sequencing analyses has
often ignored RNA viruses, whose role in the intestinal microbiome remain unclear and current
isolation procedures which are primarily designed to isolate DNA viruses, may have overlooked the
presence of RNA viruses in the intestinal virome [134]. Prior attempts at characterizing the virome
have only been able to assign 15% to 87% of virus-like particle sequences or contigs within sequence
databases [129,130,135]. This variability is a limitation of current taxonomic assignment criteria and
we are only able to report on bacteriophages that are most closely related to taxa in current databases.
This is thought to be due to rapid evolution of phages and their sequences, although it can also be due
to the initial quality of sequence reads and the proportion that were trimmed prior to analysis. It is
clear that each individual displays different viral sequence diversity, of which the full representation
of the resident viruses can only be obtained with deeper sequencing approaches. Such techniques
are required to enable the identification of regions of viral diversity that associate with the virulence
of specific viruses or disease. This is a process that requires the compilation of complete reference
databases for gene families in addition to reads that are long enough to be identifiable.
With increasing interest and expanding evidence of the role of phages in governing disease states
and the potential use of phages in combatting disease [136], interest has incorporated the role of viruses
in normal human physiology, a prime area of research of which is the contribution of the intestinal
microbiota in influencing the brain and behaviour as part of the gut-microbiota-brain axis.
5.2. The Gut-Microbiota-Brain Axis
A potential pathophysiological mechanism for ME/CFS development can be explained by
the integrated microbiota-gut-brain-axis [137], which describes the physiological links between the
microbiota and the central nervous system (CNS), the autonomic and enteric nervous system and the
hypothalamic-pituitary-adrenal (HPA) axis. Increasing evidence indicates that the microbiota can, by
as yet incompletely defined mechanisms and molecular mediators, communicate with the CNS via
immune, neural and endocrine pathways, which are likely to have effects on cognitive function and
behaviour [138].
Microbial interactions with the enteric nervous system have been demonstrated extensively using
germ-free mice, which allows the impact of colonising bacteria (coventionalisation) on mood and
cognitive function to be tested [139,140]. The physiological mechanisms by which stress can alter
the microbiota are thought to be due to its effects on intestinal physiology, altering gastrointestinal
motility and secretions via reductions in the waves of electrical activity (migrating motor complexes)
that sweep through the intestine in a regular cycle and trigger peristalsis, increasing intestinal
permeability and reducing the regenerative capacity of the intestinal mucosa, all of which serve
to alter the natural environment of intestinal microbiota. Different microbial niches within the
intestinal environment initiate the release of stress hormones such as norepinephrine, which can
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influence inter-bacterial signalling, the growth of specific pathogens in addition to their ability to
adhere to the intestinal mucosa [141]. Sudo et al. were the first to demonstrate differences in brain
function between germ-free and specific pathogen free (SPF) mice, with germ-free mice displaying
exaggerated hypothalamic-pituitary responses to mild restraint stress, through increased levels
of adrenocorticotrophic hormone (ACTH) and corticosterone release compared to SPF mice [142].
This was subsequently reversed upon conventionalisation in germ-free mice using faecal samples from
the SPF mice. Sudo et al. also demonstrated increased stress responses in germ-free mice colonised
with enteropathogenic E. coli, with subsequent reversal of stress-induced ACTH and corticosterone
levels when germ-free mice were colonised with the human commensal B. infantis; the effect of which
was partially reversed when germ-free mice were colonized with intestinal microbes from SPF mice.
Interestingly, Sudo et al. displayed this reversibility in very young mice, indicating a potential stage
in which neurones that regulate stress responses are sensitive to stimulation from the microbiota.
Stress induced in early life has been demonstrated to lead to dysbiosis in germ-free mice and has
been deemed to be a critical determinant of abnormal behaviours [143]. Furthermore, Heijtz et al.
demonstrated the influence of the intestinal microbiota in influencing synaptic brain activity, with
germ-free mice displaying increased motor activity and reduced anxiety in comparison with SPF mice
with normal microbiota, indicating the influence of intestinal microbes in brain activity and psychiatric
comorbidity [140].
Further studies have demonstrated the impact of host microbiota in controlling the maturation
and function of microglia in the CNS [144]. Most significantly, Bercik et al. conducted the first study to
demonstrate the ability for behavioral traits to be transferred between mouse strains that displayed
anxious and aggressive behaviors strains using fecal microbiota transplantation (FMT) [145].
The study of associations between autistic spectrum disorder (ASD) and the intestinal microbiota
has provided avenues for exploration in ME/CFS cohorts. Patients with ASD, like ME/CFS, have
a high prevalence of gastrointestinal dysfunction [146], which has also been linked to alterations in
microbiota composition [147,148]. A study exploring the connection between the microbiota and brain
function in ASD showed patients to have marked alterations in the microbiota, with specific alterations
in various Clostridium species [149]. Hsiao and colleagues showed a gut-microbiota-brain connection
in an adolescent mouse model of ASD (maternal immune activation, MIA), which exhibits intestinal
barrier defects and microbiota alteration [150]. Upon treatment of MIA offspring with B. fragillis,
intestinal permeability was corrected, microbial composition was altered and ASD-related deficits
in communication and behaviour were reduced. MIA offspring also displayed an altered serum
metabolomics profile, specifically key molecules in a tryptophan metabolism pathway, including
increased levels of serotonin that were restored to normal upon treatment with B. fragillis [151].
This work suggests the role of probiotic bacteria and bacterial metabolites in preventing or causing
neurodevelopment disorders respectively, suggesting an important role for the microbiota in the
development of social behaviour in ASD. Of possible interest in ME/CFS research is the sleep-inducing
substance derived from bacterial cell walls, Factor-S. Studies have suggested that intestinal bacteria
are an important source of Factor-S, especially after Brown demonstrated normal sleep patterns to be
disrupted after perturbation of the microbiota with oral antibiotics [152].
Stress, or an organism’s ability to cope with environmental demands is well known to increase
susceptibility to diseases that include gastrointestinal disorders [153]. It is also well established that
dietary and environmental stresses in turn, create different microbial niches affecting the localisation of
the different microbiota populations which can particularly favour pathogenic bacterial species [154].
This can lead to the release of stress hormones and cytokines such as IL-6 [142,155]. Bacteria too,
can respond to and synthesize hormones and neurotransmitters with for example, Lactobacillus and
Bifidobacteria species producing acetylcholine and/or gamma-amino butyrate (GABA); Escherichia
species producing norepinephrine, serotonin and dopamine; and serotonin produced by Streptococcus
and Enterococcus species [156]; all of which can contribute to the host’s regulation of mood, cognition,
pain and anxiety.
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There is clearly still much to be learned about the molecular connections and pathways involved in
gut-microbiota-brain signalling and how perturbations of this communication pathway might give rise
to disease states. The effect of the intestinal microbiota on the CNS and cognitive function represents
exciting and potentially fruitful opportunities for future investigation and explaining the manifestation
of the core symptoms of ME/CFS. Also, the advent of ‘biotics’ (probiotics and/or prebiotics) and FMT
provides opportunities to manipulate the microbiota to improve or restore gut health and impact on
how it influences the function of other organ systems, including the immune system and the CNS.
6. A Proposal for Future Research: Intestinal Dysbiosis Drives Autoimmunity in ME/CFS
It is likely that ME/CFS follows a non-classical autoimmune mechanism and it has been long
described to encompass idiopathic immune dysregulation. Based upon the evidence presented in this
review, a candidate for chronic stimulation of the immune system that triggers autoimmune processes
may be found in the intestinal virome. It is worth stressing that should phylogenetic differences in
the virome and microbiome be detected in ME/CFS patients, future research needs to be directed
towards determining the consequences of these changes and their impact on the functionality of
the microbiota. This could then provide insight into the adaptive mechanisms of commensals and
potentially pathogenic microorganisms that are required for persistence in the GI-tract, in addition
to describing how the microbiota shapes the development and function of the immune system in
these patients.
The virome evidently plays a powerful part within the microbiome, with bacteriophages being
shown to have a major impact on the dynamics and evolutionary processes of their host populations
and the identification of novel viruses is of clear interest. Roux et al. recently showed microbial hosts
to be specifically associated with particular viruses, suggesting a long-term co-evolution between the
viruses and their host [157] and indicating that profiling bacterial communities will strengthen any
association between virome composition and ME/CFS. As Norman et al. displayed in their study of
the enteric virome in inflammatory bowel disease, the power of detecting disease-associated changes
in the virome were only observed by comparing patients and household controls, controlling for
the influence of genetics and environment [158]. Future studies will need to account for within-host
variability in species level analysis by age and gender matching control participants.
The composition of the human gut virome shows significant variation to be dependent on bacterial
populations and highlights the benefits of concurrent viral and bacterial community profiling in future
microbiome studies. We propose that phages shape the bacterial microbiota through density-dependent
predation, a mechanism by which actively replicating or reactivating phages lyse their bacterial
hosts, change the abundance of specific bacterial species and induce dysbiosis [159]. Once lysed
bacteria release their cell contents comprising of proteins and nucleic acids, these products serve as
antigens and microbe-associated molecular patterns (MAMPS) that trigger mucosal host responses,
for example, via MyD88-independent pro-inflammatory cytokine production displayed in in vitro
models [160]. The ability of viruses to stimulate mucosal responses has also been considered by
the constant re-infection of viruses of low virulence and humans being chronic carriers of viruses,
which has been previously shown to be associated with increased risk of developing diseases such as
asthma [161] and type 1 diabetes [162,163].
Viral-induced inflammation can lead to increased intestinal epithelial permeability resulting in
the translocation of phages across mucosal surfaces and increased systemic exposure to microbial
epitopes [127]. Oral administration of phages in animal studies have demonstrated translocation of
phages to systemic tissues [164] and experimental studies of phage interactions with the immune
system have found free phage particles to spread systemically via breaks in the intestinal mucosa or by
dendritic cell transport, with phages being immunogenic enough to generate antibodies in human
infants [165]. These studies suggest that mammals have mechanisms for the uptake and delivery
of phage that allow intestinal phages to provoke innate and adaptive immune responses. For these
reasons, phages may serve as innate immune ligands that stimulate host immunity and inflammation,
characteristic of an environment of dysbiosis and autoimmunity.
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Previous culture-based assays characterizing the bacterial components of ME/CFS patients have
reported a reduction in the proportional abundance of Bifidobacteria species [120] that can contribute to
maintaining intestinal epithelial integrity [166]. A reduction in these beneficial Gram-positive bacteria
may favour the expansion and interaction of harmful Gram-negative bacteria within the intestinal
mucosal surface, or by removing the beneficial traits of Bifidobacteria species thereby precipitating
the symptoms of ME/CFS. For example, increased levels of Bifidobacteria have been associated with
increased plasma tryptophan levels and serotonin and dopamine production in areas of the brain
associated with depression and anxiety [167]. Additionally, studies have shown certain Bifidobacteria
species to have a significant impact on functional improvements in NK cell activity and to lower
levels of IL-4, IL-5 and IL-10 cytokines [168,169]. These effects support the presence of Th1 directed
cell-mediated immunity [170,171], important for the control of viruses and bacteria. NK cells also
interact with dendritic cells, which are in close contact with the gut epithelium and mount tolerogenic
responses to preserve immune homeostasis in the gut [172]. Any disruption to this fine-tuned interface
between bacterial species, immune function and epithelial cell barrier could give rise to inappropriate
immune responses. Given the suggested immunomodulatory properties of Bifidobacterium, it is possible
that the phages associated with Bifidobacteria species can via their influence on diversity and function
of their host bacteria initiate such downstream immunological effects. Further studies are required
investigating the interactions between keystone bacterial species, phages and the mucosal immune
responses that may provide a more complete picture of the intestinal environment in ME/CFS.
As highlighted by Goodrich et al. identifying genes associated with members of the microbiota
can provide valuable information on host-microbiota interactions [173]. Focus should now be on
understanding how phage genomes relate to each other and their hosts, and the evolutionary
mechanisms that shape phage populations. In vivo studies and animal models will strengthen
metagenomics findings, providing insights into how resident phages and eukaryotic viruses shape
commensal bacteria and their impact on host immunity and gene expression. A ‘bacteriophage
adherence to mucus’ model has been used to show that concentrated phage bound to the intestinal
mucus layer result in a dramatic decrease in bacterial attachment to the mucus and significantly
decreased damage to cultured cells [174]. Deeper, more detailed sequencing approaches and expanding
databases will certainly improve virus identification, accounting for the uncharacterized ‘dark matter’
of the human enteric virome.
7. Concluding Remarks
While studies have to date failed to identify a distinct microbial signature that establishes
a pathogenic role of the intestinal microbiota in ME/CFS, a cycle of chronic intestinal dysfunction
and instability of the microbiota certainly characterizes a subset of patients with ME/CFS. Pursuing
the role of intestinal microbial dysbiosis in the pathophysiology of ME/CFS may well establish how
immunological dysregulation manifests in its core symptoms. The use of next-generation sequencing
techniques and metagenomic tools may identify predictors of disease relapse and chronicity [175],
with the technology continually being tailored for use on viral ecosystems [176,177]. Analogous to
IBD studies, microbiota characterization may elucidate more distinct subpopulations within current
ME/CFS classifications. Ultimately, observing any association between microbial phylogeny and
the ME/CFS disease phenotype can highlight the impact of the microbial community on human
health, and has the potential to identify disease biomarkers and influence therapeutics, providing
much-needed approaches in preventing and managing a disease in need of confronting.
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